Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS181 in Healthy Adults With Influenza
NCT01037205Phase 2Completed
- Sponsor
- Ansun Biopharma
- Start
- Dec 2009
- Primary completion
- Sep 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DAS181 in influenza (3 arms), sponsored by Ansun Biopharma. Primary endpoints: Influenza Viral Load Area Under the Curve at Day 5 and Unacceptable Serious Adverse Events at 28 days. Started Dec 2009; status: completed.
02
Drugs
DAS181
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01037205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037205.